ENDRA Life Sciences (NDRA) Registration Filing summary

Company overview and business model

• Developing Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology, initially targeting liver fat measurement.

• Recently adopted a digital asset treasury (DAT) strategy, allocating excess cash to cryptocurrencies, primarily HYPE.

• Formed a Digital Asset Advisory Board and engaged Arca Investment Management for active asset management of digital assets.

• Plans to license TAEUS technology to OEMs and integrate with existing ultrasound systems.

Financial performance and metrics

• No revenue generated from TAEUS technology as of the prospectus date.

• Stock price on Nasdaq ranged from $2.90 to $11.96 between January and September 2025.

• As of October 16, 2025, 1,166,441 shares of common stock were outstanding.

Use of proceeds and capital allocation

• Will not receive proceeds from resale by selling stockholders; will receive proceeds from any cash exercises of warrants.

• Majority of net proceeds from recent private placement intended for DAT strategy, with up to $750,000 allocated to a pilot validation study for the TAEUS liver device.

• Future offerings may be used to purchase additional cryptocurrency, subject to market conditions.